Boundless Bio, Inc. (BOLD) Income Statement
BOLD 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBOLD revenue and net income
BOLD growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BOLD quarterly EPS vs estimates
Boundless Bio beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 4, 2026.
BOLD income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.3M | $1.1M | $957,000 | $942,000 | $682,000 | — | — | — |
| Gross profit | −$1.3M | −$1.1M | −$957,000 | −$942,000 | −$682,000 | — | — | — |
| Research & development | $44.8M | $55.3M | $42.6M | $37.2M | $19.3M | $104.4M | $75.9M | $48.8M |
| Sales, general & admin | $18.7M | $18.0M | $12.2M | $9.3M | $6.0M | $30.0M | $17.3M | $11.3M |
| Total operating expenses | $62.3M | $72.2M | $54.8M | $46.5M | $25.3M | $134.4M | $93.2M | $60.0M |
| Operating income | −$63.6M | −$73.3M | −$54.8M | −$46.5M | −$25.3M | −$134.4M | −$93.2M | −$60.0M |
| Interest income | $5.4M | $7.9M | $5.3M | $668,000 | $96,000 | — | — | — |
| Income before taxes | −$58.2M | −$65.4M | −$49.4M | −$45.9M | −$25.2M | −$128.8M | −$92.5M | −$59.7M |
| Income taxes | — | −$65.4M | −$5.3M | −$668,000 | −$96,000 | $5.6M | −$2.2M | $378,000 |
| Net income | −$58.2M | −$65.4M | −$49.4M | −$45.9M | −$25.2M | −$128.8M | −$90.2M | −$59.7M |
| EBITDA | −$56.9M | −$64.3M | −$48.5M | −$45.0M | −$24.5M | −$121.4M | −$88.7M | −$58.1M |
| EPS (diluted) | −$2.61 | −$14.52 | −$12.90 | −$2.06 | — | −$3.40 | −$3.40 | −$8.28 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $1.1M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $284,000 | $307,000 | $310,000 | $317,000 | $317,000 | $296,000 | $262,000 | $265,000 | $263,000 | $247,000 | $235,000 |
| Gross profit | — | −$284,000 | −$307,000 | −$310,000 | −$317,000 | −$317,000 | $528,000 | −$262,000 | −$265,000 | −$263,000 | −$247,000 | −$235,000 |
| Research & development | $14.0M | $9.7M | $10.4M | $10.4M | $11.9M | $12.1M | $13.3M | $14.1M | $14.5M | $13.1M | $10.4M | $11.6M |
| Sales, general & admin | $10.4M | $4.7M | $4.2M | $4.5M | $4.8M | $5.2M | $5.0M | $4.6M | $4.7M | $3.8M | $3.4M | $3.3M |
| Total operating expenses | $24.4M | $14.2M | $13.7M | $14.8M | $16.7M | $17.3M | $18.3M | $18.7M | $19.1M | $16.9M | $13.8M | $15.0M |
| Operating income | −$24.4M | −$14.5M | −$14.0M | −$15.1M | −$17.1M | −$17.3M | −$18.3M | −$18.7M | −$19.4M | −$16.9M | −$13.8M | −$15.0M |
| Interest income | $690,000 | $920,000 | $1.1M | $1.3M | $1.4M | $1.6M | $1.9M | $2.2M | $2.4M | $1.4M | $1.6M | $1.7M |
| Income before taxes | −$23.7M | −$13.6M | −$12.9M | −$13.9M | −$15.7M | −$15.8M | −$16.4M | −$16.5M | −$17.0M | −$15.4M | −$12.1M | −$13.2M |
| Income taxes | — | — | — | — | — | — | — | — | — | $219,724 | −$1.6M | −$1.7M |
| Net income | −$23.7M | −$13.6M | −$12.9M | −$13.9M | −$15.7M | −$15.8M | −$16.4M | −$16.5M | −$17.0M | −$15.4M | −$12.1M | −$13.2M |
| EBITDA | −$22.4M | −$13.3M | −$12.6M | −$13.6M | −$15.4M | −$15.4M | −$16.2M | −$16.2M | −$16.7M | −$15.2M | −$11.9M | −$12.9M |
| EPS (diluted) | −$1.06 | −$0.60 | −$0.58 | −$0.62 | −$0.70 | −$0.71 | −$0.74 | −$0.74 | −$0.77 | −$12.27 | −$9.76 | — |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −1,730.9% | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | −1,557.6% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BOLD's financial statements (latest annual report filed March 9, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BOLD financial results
Boundless Bio reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $58.2 million. Diluted earnings per share came to −$2.61.
See the BOLD stock overview for the latest quote and news, or the BOLD chart for price history and technical indicators.
BOLD income statement FAQ
Does Boundless Bio have revenue?
Boundless Bio reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Boundless Bio profitable?
No. Boundless Bio reported a net loss of $58.2 million in fiscal 2025.
How much does Boundless Bio spend on research and development?
Boundless Bio spent $44.8 million on research and development in fiscal 2025.
What are Boundless Bio's earnings per share?
Boundless Bio earned $-2.61 per diluted share in fiscal 2025, compared with $-14.52 a year earlier.
When will Boundless Bio report its next earnings?
Boundless Bio is expected to report results for the quarter ending September 30, 2026 on November 4, 2026.
When does Boundless Bio's fiscal year end?
Boundless Bio's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 9, 2026.